Drug intelligence / Profile preview

[18F]F-RESCA-RD06

Development stage: Phase 2
Lead developer: Renji Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]F-RESCA-RD06 is a radiopharmaceutical imaging agent developed by RenJi Hospital (Shanghai Jiao Tong University School of Medicine) for the detection of CD70-expressing malignancies. It consists of a CD70-specific nanobody (single-domain antibody) labeled with fluorine-18 using the restrained complexing agent (RESCA) method, which allows for efficient radiolabeling via the aluminum-fluoride ([18F]AlF) complex. CD70 is a cell surface antigen highly expressed in clear cell renal cell carcinoma (ccRCC), certain lymphomas, and nasopharyngeal carcinoma, while having limited expression in normal tissues. This tracer is utilized in immuno-PET/CT imaging to evaluate tumor burden, guide treatment selection, and monitor response in patients with CD70-positive cancers.

Other names: [18F]AlF-RESCA-RD06CD70-targeted immuno-PET tracer RD06CD-70-targeted immuno-PET tracer RD06CD 70-targeted immuno-PET tracer RD06

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on [18F]F-RESCA-RD06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]F-RESCA-RD06.

Explore the full profile